Updated April 2026 · USPTO PatentsView
When Does Cosentyx Patent Expire?
Cosentyx is protected by 9 US patents in the USPTO records tracked here. The earliest patent expires on Mar 9, 2026 (0 years from now), opening the door to potential generic or biosimilar competition for that specific composition. Full portfolio protection extends to Dec 26, 2041. Overall Patent Strength Score: 34/100 (Grade F, "very weak").
Cosentyx Patent Snapshot
| Total US Patents | 9 |
| Earliest Patent Expiration | Mar 9, 2026 |
| Latest Patent Expiration | Dec 26, 2041 |
| Years Until First Expiry | Already expired |
| Patent Holder | Novartis AG |
| Generic Name | cosentyx |
| Patent Strength Score | F34/100 |
When the Cosentyx Patent Cliff Hits
The earliest patent in the Cosentyx portfolio has already lapsed (2026), so generic or biosimilar competitors are legally clear to enter the market for that specific composition or method. Later patents extending to 2041 may still cover specific formulations, dosing regimens, or manufacturing processes — these "secondary" patents are commonly the subject of Paragraph IV challenges by generic drug makers.
Because Cosentyx's earliest patent has already expired, generic versions are technically clear to enter the market for that specific patented composition. Whether a generic is actually available depends on FDA Orange Book listings for any later patents, ANDA approvals, and any ongoing Paragraph IV settlements. Patients and prescribers should check the FDA's Orange Book or GoodRx for current generic availability.
For the authoritative listing of patents tied to a specific drug — the patents an ANDA filer is legally required to address under 21 USC § 355(j) — consult the FDA Orange Book. Underlying utility patent data on this page is sourced from USPTO PatentsView, the federal government's free public patent API.
Inside the Cosentyx Patent Portfolio
Cosentyx is protected by 9 US patents, a mid-sized portfolio that is typical for an established branded drug in mid-lifecycle. The portfolio likely combines a primary composition-of-matter patent (the strongest form of protection) with a layer of formulation, dosing, and method-of-use patents that extend exclusivity beyond the original composition expiry — a common strategy known as "patent layering" or, less charitably, "evergreening."
All 9 patents in the Cosentyx portfolio are assigned to Novartis AG, indicating consolidated ownership. Single-assignee portfolios are simpler to litigate and easier to license — generic challengers face one negotiating counterparty, and any settlement or pay-for-delay arrangement involves only that holder.
The Cosentyx portfolio scores 34/100 (Grade F, "very weak") on the PatentCliff Strength index. The strongest signal is claims breadth (67/100), and the weakest is technology diversity (15/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.
Earliest Patents in the Portfolio
| Patent # | Title | Expires | Years Left |
|---|---|---|---|
| 10005647 | Method for preparing advanced CMOS derivatives | 2026 | expired |
| 10005649 | Method for adaptive diagnosis using nano-scale | 2029 | 2.7 |
| 10005650 | multi-layer CMOS enzymatic process | 2030 | 3.8 |
| 10005646 | distributed analog enzymatic process | 2032 | 5.8 |
| 10005648 | Recombinant digital protein with scalable activity | 2032 | 6.1 |
| 10005643 | Method of treating disease using dynamic cloud therapy | 2033 | 7.7 |
| 10005651 | Pharmaceutical composition comprising enhanced cloud compoun… | 2034 | 7.9 |
| 10005645 | Recombinant 5G protein with low-latency activity | 2036 | 10.1 |
Cosentyx vs Other Branded Drugs
Cosentyx's 9-patent portfolio is 28% smaller than the average drug tracked here (12 patents) — lighter-than-typical lifecycle protection. Among the 40 drugs in this database, Cosentyx ranks #31 by patent count. For broader context, the earliest expiration in the data set is Biktarvy (2025) and the longest-protected drug is Wegovy (latest expiry 2040).
Expiration Timeline
Looking at the 9 dated patents in the portfolio, the largest cluster (5 patents) falls in the "5–10 years (2032–2036)" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.
The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.
How the Patent Strength Score Is Calculated
The PatentCliff Strength Score combines four signals from USPTO data into a single 0-100 grade. Portfolio size (30%) measures the number of patents covering the drug — a proxy for litigation depth and the count of independent challenges a generic must clear. Claims breadth (25%) is the average number of claims per patent, an indicator of how broadly each patent attempts to cover the underlying invention. Time remaining (25%) measures average years until expiration across the portfolio. Technology diversity (20%) measures the number of distinct CPC (Cooperative Patent Classification) classes the portfolio touches — diverse portfolios are harder to design around. Read the full PatentCliff methodology, including how scores compare to citation-weighted academic measures.
Sources: Patent records — USPTO PatentsView API (public domain). Drug-to-patent mapping cross-referenced against the FDA Orange Book. Expiration dates calculated as application date plus 20 years per 35 USC § 154.
Cite as: "PatentCliff, April 2026 reading. Source: USPTO PatentsView." Last updated 2026-04-10.
The data source behind this answer is the FDA Orange Book and USPTO patent records. Every figure on the page traces back to that source; the methodology page describes the inputs and the refresh cadence in full detail.
For readers turning this answer into action: cross-reference against the underlying the FDA Orange Book and USPTO patent records record before acting on time-sensitive decisions. The site renders the data as it was published; subsequent revisions can shift the picture, and the live federal data is always the authoritative current reference.